_edited.png)
Wockhardt Ltd
Soars 11.5% to a Record High - Has a 13-Year Breakout Finally Found Its Trigger ?
Wockhardt shares surged 11.5% to an all-time high after the company received regulatory approval for its newly developed antibiotic, Zaynich. The breakthrough drug, aimed at treating complex bacterial infections, has reignited investor interest, helping the stock break out of a 13-year consolidation phase and emerge as one of the top-performing stocks in the Nifty 500.
The primary catalyst behind Wockhardt's sharp rally was the approval from the Central Drugs Standard Control Organisation (CDSCO) to market Zaynich in India. The antibiotic is a combination of Zidebactam and Cefepime and is approved for treating complicated urinary tract infections (cUTI), including kidney infections and cases accompanied by Gram-negative bacteremia—a serious bloodstream infection. The approval marks a significant milestone for Wockhardt's innovation-driven pharmaceutical business.
Beyond the immediate approval, investors are focusing on the commercial potential of Zaynich. While the domestic market opportunity is estimated at ₹150–200 crore annually, the global addressable market is estimated at around $5 billion. Given the increasing global challenge of antimicrobial resistance, successful commercialization of the drug could open a meaningful long-term growth avenue for the company.
The rally is particularly noteworthy because it has pushed Wockhardt out of a consolidation range that lasted more than a decade. The stock touched a record high of ₹1,975.50 and has gained around 36% during the month. Market participants view this breakout as a strong technical signal, supported by rising volumes and improving sentiment around the company's pharmaceutical pipeline.
Technical indicators continue to reflect strong buying interest. The stock is trading above all major moving averages, ranging from the 5-day to the 200-day average, indicating a sustained uptrend. Its Relative Strength Index (RSI) stands above 70, suggesting strong momentum, although it also signals that the stock may be entering overbought territory in the near term.
Wockhardt's rally is being driven by more than just a regulatory approval. Investors are increasingly assigning value to the company's research-driven business model, innovative anti-infective pipeline, and the significant global market opportunity for Zaynich. The combination of a major product approval, long-awaited technical breakout, and strong growth potential has turned Wockhardt into one of the most closely watched pharmaceutical stocks in the market.
Latest News
TVS Motor Shares In Focus After Q2 Profit Jumps 50 Percent As Brokerages See Upside
TVS Motor reported a 50.2 percent year on year increase in consolidated net profit to Rs 1194.51 crore for Q2 FY27, while revenue from operations rose 38.6 percent to Rs 19474.44 crore. Strong volume growth, improving profitability, electric vehicle sales and export momentum have led brokerages to maintain a positive outlook on the stock.
4:36 pm
29 October 2026
BLS Polymers IPO Subscription Crosses 45 Times On Final Day
The BLS Polymers IPO remained in strong demand on the final day of bidding, with the issue subscribed 46.74 times by 10:15 am on October 29, according to NSE data. Non institutional investors led the subscription with bids exceeding 116 times the shares reserved for the category, while the grey market premium rose to 34 percent.
4:08 pm
29 October 2026
Bandhan Bank Shares Rise After Q2 Profit Jumps More Than Fivefold as Brokerages Cut Target Prices
Bandhan Bank shares gained around 1.5% on October 29, 2026, after the lender reported a second-quarter net profit of ₹622 crore, compared with ₹112 crore in the corresponding year-ago period. Despite the sharp improvement in profitability, Nomura retained its Neutral rating and reduced its target price to ₹175 from ₹190, while CLSA also lowered its price view.
3:55 pm
29 October 2026
Brent Crude Falls Below 115 Dollars As US Iran Peace Hopes Ease Supply Fears
Brent crude futures fell below 115 dollars a barrel while WTI crude traded near 101 dollars as hopes of US Iran peace talks eased concerns over a widening Middle East conflict. The decline came despite continued uncertainty over regional tensions and their potential impact on global oil supplies.
3:20 pm
29 October 2026
Bitcoin Falls Below 80000 as Hawkish Fed Stance Fuels Caution
Bitcoin fell below the 80000 level to around 79750 as a hawkish Federal Reserve stance increased caution among crypto investors. The decline came despite continued inflows into US spot Bitcoin exchange traded funds, with investors closely watching support levels, ETF flows and upcoming US economic data.